Trial Profile
Comparative Efficacy of Ticagrelor Versus Aspirin on Blood Viscosity in Peripheral Artery Disease (PAD) Patients With Type 2 Diabetes (T2D)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Mar 2022
Price :
$35
*
At a glance
- Drugs Aspirin (Primary) ; Ticagrelor (Primary)
- Indications Peripheral arterial occlusive disorders; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 18 Mar 2019 Results assessing the effectiveness of ticagrelor and aspirin than aspirin monotherapy in patients with lower extremity arterial disease and type 2 diabetes mellitus, presented at the 68th Annual Scientific Session of the American College of Cardiology.
- 01 Nov 2018 Status changed from recruiting to completed.
- 26 Sep 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.